JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Начало・Списък с акции・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

25 -0.79

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.83

Максимум

25.33

Ключови измерители
By Trading Economics
Приходи	675K 53M
Продажби	1.8M 148M
P/E Средно за сектора	14.62 84.243
Марж на печалбата	35.57
Служители	181
EBITDA	1.7M 80M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+36% upside

Дивиденти
By Dow Jones
Следващи печалби	25.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	449M 3.1B
Предишно отваряне	25.79
Предишно затваряне	25

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

N/A / 24.28 Подкрепа & съпротива

Catalyst Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.02.2026 г., 22:55 ч. UTC

Печалби

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4.02.2026 г., 21:44 ч. UTC

Печалби

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4.02.2026 г., 21:39 ч. UTC

Печалби

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

4.02.2026 г., 23:46 ч. UTC

Печалби

Arm Holdings Expects Slower Revenue Growth in 4Q -- Update

4.02.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4.02.2026 г., 23:45 ч. UTC

Горещи акции

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4.02.2026 г., 23:45 ч. UTC

Печалби

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4.02.2026 г., 23:32 ч. UTC

Пазарно говорене

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4.02.2026 г., 22:59 ч. UTC

Придобивния, сливания и поглъщания

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4.02.2026 г., 22:30 ч. UTC

Печалби

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4.02.2026 г., 22:30 ч. UTC

Печалби

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4.02.2026 г., 22:21 ч. UTC

Печалби

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4.02.2026 г., 22:17 ч. UTC

Пазарно говорене

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4.02.2026 г., 22:15 ч. UTC

Пазарно говорене

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4.02.2026 г., 22:00 ч. UTC

Пазарно говорене

ESG Roundup: Market Talk

4.02.2026 г., 21:53 ч. UTC

Печалби

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4.02.2026 г., 21:51 ч. UTC

Печалби

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Auto & Transport Roundup: Market Talk

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

4.02.2026 г., 21:45 ч. UTC

Печалби

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4.02.2026 г., 21:44 ч. UTC

Печалби

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4.02.2026 г., 21:43 ч. UTC

Печалби

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4.02.2026 г., 21:41 ч. UTC

Печалби

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4.02.2026 г., 21:36 ч. UTC

Пазарно говорене

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4.02.2026 г., 21:30 ч. UTC

Печалби

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4.02.2026 г., 21:30 ч. UTC

Печалби

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4.02.2026 г., 21:30 ч. UTC

Печалби

Beach Energy Interim Dividend 1 Australian Cent/Sjare

4.02.2026 г., 21:30 ч. UTC

Печалби

Steris Sees FY Adj EPS $10.15-Adj EPS $10.30 >STE

Сравнение с други в отрасъла

Ценова промяна

Catalyst Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

36% нагоре

12-месечна прогноза

Среден 34 USD 36%

Висок 35 USD

Нисък 33 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Catalyst Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Catalyst Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 24.28Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.